

Attorney Docket No.: **ISIS-5315 (ISIS No ISIS-2960US.P2)**
Serial No.: **10/698,689**
Page 5

REMARKS

Claims 1-69 are pending in the instant application. An Office Action has restricted the pending claims into the following groups:

Group I: Claims 1-16, 22, 28-61, 68 and 69, drawn to oligonucleotides targeted to CD40;

Group II: Claims 17, 18, 23-27 and 62-67, drawn to a method of inhibiting expression of CD40 with an antisense oligonucleotide;

Group III: Claims 19 and 20, drawn to a method of screening for a modulator of CD40; and

Group IV: Claim 21, drawn to a diagnostic method to identify a disease state.

The Applicants elect Group II, claims 17, 18, 23-27 and 62-67, without traverse. The remaining claims have been canceled. The Applicants reserve the right to file divisional applications on the remaining claims.

The Applicants thank the Examiner for the telephone call indicating that the limitations of claims 1 and 57 needed to be explicitly incorporated into claims 17, 23, 62, 66, and 67 as claims 1 and 57 were no longer pending in the instant case. The Examiner did not require an election of species in conjunction with the election of group II.

I. Fees

It is believed that no fee is due with this response as the first response was a bona fide attempt to respond to the restriction requirement.. However, if an additional fee is due, the Commissioner is hereby entitled to charge the fee to the Deposit Account 500252, referencing case ISIS-2960US.P2.

Attorney Docket No.:

ISIS-5315 (ISIS No ISIS-2960US.P2)

Serial No.:

10/698,689

Page 6

II. Conclusion

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record. Accordingly, an early office action on the merits of the case is respectfully requested.

Date:

Jan 17, 2006

Isis Pharmaceuticals
1896 Faraday Avenue
Carlsbad, CA 92008

Respectfully submitted,



Colleen J. McKiernan, PhD
Registration No. 48,570

Phone: 760-603-2722
Facsimile: 760-603-3820